Anna Wienner – General Manager, IBSA Hungary
Anna Wienner, general manager of IBSA Hungary, gives an update on the recent activities and achievement of the affiliate since her previous interview in 2016. Furthermore, Wienner goes on to…
IBSA Institut Biochimique SA is a privately owned, pharmaceutical company founded in 1945 by a group of Swiss biologists. Based in Lugano, Switzerland, IBSA started its activities at a national level but rapidly became a well consolidated company worldwide. IBSA markets its products in 4 continents which means more than 70 countries, including the US. IBSA’s history can be divided into 2 main periods from its beginning 1945 to 1985 when the current management took over and completely re-defined the company strategy leading to the first international development and to its present global reputation.
As a result of this massive commercial revolution, IBSA currently has a head count of about 1800 employees and its products cover 7 main therapeutic areas in 4 continents and more than 70 countries. Each year the company manufactures about 12 millions vials of hormones, more than 200 millions soft gel capsules and about 60 millions packages of finished products. These are the numbers of a well-deserved success.
The company’s first foreign subsidiary was founded in 1995 in Budapest, Hungary. The subsidiary has 21 years of unbroken success, with a dedicated and hardworking staff whose efforts truly demonstrate the impeccable quality and competitive prices that the IBSA brand embodies.
Contact
1124 Budapest, Fodor u. 54 / B
Tel: (1) 225-7775
Fax: (1) 201-7772
Email: ibsa@ibsa.hu
Anna Wienner, general manager of IBSA Hungary, gives an update on the recent activities and achievement of the affiliate since her previous interview in 2016. Furthermore, Wienner goes on to…
To effectively reform old habits requires diligence, consistency and, above all, patience. As an introduction for our readers, could you describe the initial objectives that you set for yourself…
Providing universal health coverage to the nation’s roughly 10 million citizens, Hungary’s National Health Insurance Fund (OEP) has one of the most comprehensive and complex structures in Europe. The organization’s…
Chronic underfinancing is a common pitfall for many former socialist states and Hungary is no exception. Total health spending ultimately accounted for 8.0 percent of GDP in Hungary in 2014, which…
Mylan Hungary’s Tamas Uri discusses transitioning into both a branded and generic business dedicated company, Mylan’s expansion in Hungary, and how the pharmaceutical industry can be a key player in improving the…
Hungary’s Minister of Foreign Affairs and Trade Péter Szijjártó highlights the significant role that foreign direct investments have played in developing the country’s healthcare and life science sector, while detailing…
György Bodoky, Head of the Oncology Department at Unified Szent István and Szent László Hospital, shares his insights on the state of oncological care in Hungary, the current effects of…
János Burovincz, Managing Director of Patent, shares his insights on building a company from scratch, the importance of maintaining a diverse portfolio that can quickly adapt to market needs as…
GSK Hungary’s Claire Roger discusses the value of ethical promotion both in improving transparency and benefiting all stakeholders. She further describes the strategic role and economic impact of GSK’s vaccine plant in…
Róbert Ésik, President of the Hungarian Investment Promotion Agency (HIPA), shares his insights into what makes Hungary such an attractive destination for foreign direct investment and ways that the agency…
To effectively reform old habits requires diligence, consistency and, above all, patience. As an introduction for our readers, could you describe the initial objectives that you set for yourself…
Veronika Ferencz, Sales and Marketing Director for Exeltis Hungary, discusses the evolving and expanding footprint of the company in Hungary, the challenges strict regulations on food supplements are causing, as…
The leadership of Meditop discuss their history as the first non-privatized, private Hungarian pharmaceutical company, their ongoing strategies for growth in the country, and their evolving portfolio abroad. They also…
The recently appointed CEO of Servier Hungary, Dr. Jan Frederic Kesselhut highlights his initial perceptions of the Hungarian pharmaceutical market and depicts the significant role that the Servier Research Institute…
See our Cookie Privacy Policy Here
